Thursday, April 30, 2020 11:21:23 AM
Are you claiming that CR was a "primary outcome"? Below from Clinical Trial website-
Primary Outcome Measures :
1) Number of patients with treatment related serious adverse events [ Time Frame: 7 months ]
To determine the safety of up to 6 intravenous infusions of multiTAA-specific T cells in pancreatic cancer patients with metastatic, locally advanced unresectable, or resectable disease.
2) Number of patients who received 6 infusions of multiTAA-specific T cells [ Time Frame: 6 months ]
To determine the feasibility of completing a total of 6 intravenous infusions of multiTAA-specific T cells to pancreatic cancer patients with metastatic, locally advanced unresectable, or resectable disease
Secondary Outcome Measures :
1) Progression Free Survival using the Kaplan-Meier method [ Time Frame: 5 years ]
To evaluate the progression-free of patients after multiTAA-specific T cell infusions
2) Overall Survival using the Kaplan-Meier method [ Time Frame: 5 years ]
To evaluate the overall survival of patients after multiTAA-specific T cell infusions
---------------------------------------------------------
There has been a lot of hope expressed for another CR, but that's just what some people would like to see.
Primary Outcome Measures :
1) Number of patients with treatment related serious adverse events [ Time Frame: 7 months ]
To determine the safety of up to 6 intravenous infusions of multiTAA-specific T cells in pancreatic cancer patients with metastatic, locally advanced unresectable, or resectable disease.
2) Number of patients who received 6 infusions of multiTAA-specific T cells [ Time Frame: 6 months ]
To determine the feasibility of completing a total of 6 intravenous infusions of multiTAA-specific T cells to pancreatic cancer patients with metastatic, locally advanced unresectable, or resectable disease
Secondary Outcome Measures :
1) Progression Free Survival using the Kaplan-Meier method [ Time Frame: 5 years ]
To evaluate the progression-free of patients after multiTAA-specific T cell infusions
2) Overall Survival using the Kaplan-Meier method [ Time Frame: 5 years ]
To evaluate the overall survival of patients after multiTAA-specific T cell infusions
---------------------------------------------------------
There has been a lot of hope expressed for another CR, but that's just what some people would like to see.
Recent MRKR News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 09:00:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/04/2026 08:30:23 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/20/2026 08:08:49 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/20/2026 08:07:05 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/20/2026 08:05:49 PM
- Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results • GlobeNewswire Inc. • 03/18/2026 09:31:30 PM
- Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference • GlobeNewswire Inc. • 02/18/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 09:06:45 PM
- Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology • GlobeNewswire Inc. • 01/26/2026 12:00:00 PM
- Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer • GlobeNewswire Inc. • 01/05/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:10:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/19/2025 09:01:15 PM
- Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 11/17/2025 09:22:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 12:20:47 PM
- Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates • GlobeNewswire Inc. • 11/14/2025 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/13/2025 10:29:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/05/2025 12:36:59 PM
- Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors • GlobeNewswire Inc. • 11/05/2025 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:09:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 10:03:27 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 11/04/2025 09:54:39 PM
- Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting • GlobeNewswire Inc. • 11/03/2025 02:15:00 PM
- Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program • GlobeNewswire Inc. • 10/06/2025 11:30:59 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2025 11:30:37 AM
